trial

Polypharmacy in Clozapine-resistant Schizophrenia

NCTId NCT00918021
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 30 (actual)
Sponsored by Niuvanniemi Hospital
Primary completion 2010-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-06
Primary completion
2010-07
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Niuvanniemi HospitalLead Sponsor

Investigators

1
Jari Tiihonen, MD, PhDPrincipal Investigator

Sites

1 total
Kuopio, Finland

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE4
Primary Completion Date
2010-07
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Niuvanniemi Hospital
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Jari Tiihonen, MD, PhD
person